Overview

Bevacizumab Plus Modified FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma, Single-arm, Phase II Study

Status:
Recruiting

Trial end date:
2025-02-01

Target enrollment:

Participant gender:

Summary

This research study is evaluating a modified FOLFIRINOX plus bevacizumab therapy for mucinous ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Yonsei University

Treatments:

Bevacizumab
Folfirinox